research use only

Darunavir HIV Protease inhibitor

Cat.No.S5250

Darunavir (TMC114,DRV) is a nonpeptidic HIV protease inhibitor, used to treat HIV infection.
Darunavir HIV Protease inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 547.66

Jump to

Quality Control

Batch: S525001 DMSO]100 mg/mL]false]Ethanol]11 mg/mL]false]Water]Insoluble]false Purity: 99.89%
99.89

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (182.59 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 11 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 547.66 Formula

C27H37N3O7S

Storage (From the date of receipt)
CAS No. 206361-99-1 -- Storage of Stock Solutions

Synonyms TMC114,DRV Smiles CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N

Mechanism of Action

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06139796 Not yet recruiting
HIV Infections
PENTA Foundation|AMS-PHPT Research Collaboration|Institut National de la Santé Et de la Recherche Médicale France|Centre Mère et Enfant de la Fondation Chantal Biya|Centre Hospitalier National d''Enfants Albert Royer|University of Zimbabwe Clinical Research Centre (UZCRC)|Baylor College of Medicine
June 2024 Phase 1|Phase 2
NCT06005610 Recruiting
HIV I Infection
National Institute of Allergy and Infectious Diseases (NIAID)
January 4 2024 Phase 2
NCT05506605 Active not recruiting
HIV-1-infection
Fundacion Clinic per a la Recerca Biomédica
December 12 2022 Phase 4
NCT05197075 Completed
Human Immunodeficiency Virus (HIV)
Janssen Research & Development LLC
August 3 2022 Phase 1
NCT05378906 Completed
Healthy
Janssen Research & Development LLC
June 7 2022 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map